RNASE3

Across TCGA pan-cancer cohorts, RNASE3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RNASE3 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RNASE3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RNASE3 expression acts as an unfavorable survival marker.

LIHC and BLCA are the cancer types where RNASE3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.105	0.777	<.001	9	view →
BLCA	OS	Median	IV	0.120	0.599	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RNASE3–LIHC (OS)

Open the LIHC breakdown →